Oral GLP-1s expand the obesity drug market by an order of magnitude, and Lilly's manufacturing lead compounds
Claim. Injectable GLP-1s captured early adopters. Oral formulations (Lilly's orforglipron, Novo's oral semaglutide) collapse the friction barrier — no needle, simpler cold chain, easier prescribing. Combined with Medicare access expanding July 2026, the addressable market goes from millions to tens of millions. Lilly's $4.2B incremental manufacturing capex positions it to be supply-constrained less often than Novo.
The thesis
The story isn't 'GLP-1s exist' anymore — that's priced in. The next leg is (1) oral delivery expanding adherence, (2) US payer coverage broadening (Medicare access for Zepbound from July 1, 2026), (3) combination therapies (Zepbound+Taltz, etc.) opening adjacencies in cardio, psoriasis, sleep apnea, addiction. Lilly looks better positioned than Novo on manufacturing capacity and pipeline breadth; Novo is cheaper and may mean-revert but the operational gap is real. A barbell of LLY core + small NVO recovery position is reasonable; we'll start with LLY only.
Candidate tickers
- LLY core — Orforglipron oral approval, Medicare access from July, broadest indication pipeline.
- NVO watching — Down significantly from peaks. Cheap but operational issues real. Wait for clear pipeline catalyst before adding.
Evidence
- $3B Netherlands + $1.2B Puerto Rico oral mfg expansion.
- From consolidation to acceleration — oral approvals and access broadening.
- US gov agreement expands obesity drug access.
- Multiple orals and combos advancing through Phase 3.
Falsifiers — what would change my mind
- Orforglipron real-world adherence/efficacy materially below trial data after launch.
- Payer coverage rollback or Medicare formulary exclusion.
- Manufacturing yields below plan for two consecutive quarters.
- New entrant with materially better safety/efficacy profile (e.g., amycretin) closer to approval than expected.